Article Text

Download PDFPDF
MET mutation and familial gastric cancer
  1. J D Chena,
  2. S Kearnsa,
  3. T Porterb,
  4. F M Richardsb,
  5. E R Maherb,
  6. B T Teha
  1. aLaboratory of Cancer Genetics, Van Andel Research Institute, 333 Bostwick NE, Grand Rapids, MI 49503, USA, bSection of Medical and Molecular Genetics, Department of Paediatrics and Child Health, University of Birmingham, Birmingham B15 2TT, UK
  1. Dr Teh, bin.teh{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Editor—Approximately 10% of gastric cancers show familial clustering and case control studies have identified a threefold increased risk of the disease in the first degree relatives of affected subjects.1 Gastric cancer susceptibility is a well recognised feature of hereditary non-polyposis colorectal cancer syndrome and may be associated with familial polyposis coli, Peutz-Jeghers syndrome, and germlinep53 mutations.1 2 In addition, germline E-cadherin gene (CDH1) mutations cause familial diffuse gastric cancer.3-5 However, most familial gastric cancer patients do not have germline CDH1mutations.1 6 Very recently, Lee et al 7 described a germlineMET mutation (P1009S) in a patient with primary gastric cancer, although no detailed family history was available. In contrast with MET gene mutations in the tyrosine kinase domain, which are associated with hereditary type 1 papillary renal cell carcinoma …

View Full Text